Interview
a16z Podcast | The Science Of Extending Life
- The primary goal of lifespan extension is to extend health span and reduce the period of disability at the end of life rather than to achieve immortality, with a focus on applying knowledge to mammals to improve human health.
- A conceptual shift toward "geroscience" over the last decade aims to delay or prevent the onset of all age-related diseases by slowing the aging process, moving the field from theoretical concepts like caloric restriction to mechanistic interventions.
- Recent breakthroughs in invertebrates have translated to mammalian successes in the last decade, including rapamycin treatment and senescent cell clearance in mice, which demonstrated a 30% lifespan increase and serves as a model for future human therapies.
- New genomic technologies and non-invasive biomarkers for biological age are expected to accelerate discovery by allowing researchers to measure intervention effectiveness over a one-year basis without waiting decades for clinical outcomes.
- Research into circulating blood factors suggests that infusions from young animals can revert aging phenotypes in older subjects, leading to the development of protein therapies, antibodies, or vaccines targeting aging factors.
- Senolytic therapy is being pursued as a small-molecule pill to kill senescent cells, with expectations of potential monthly dosing, though long-term safety and the necessity of eliminating all such cells remain uncertain.
- The search for drugs to target aging includes evaluating metformin for delaying disease onset via the TAME trial and investigating rapamycin, with the hope of establishing a regulatory precedent for treating aging in healthy individuals.
- Companies are expected to pursue specific disease indications to secure regulatory approval before broadening therapy applications, facing the risk that failure in narrow areas could cause the entire approach to be discarded.
- Near-term interventions are projected to add 10 to 20 years of healthy life, with plasma infusions for conditions like early-onset Alzheimer's potentially becoming treatments in the short term.
- Small molecule treatments are anticipated to lead the market and eventually become inexpensive generics, while broader adoption may rely on insurance coverage for cost savings similar to preventive measures like seat belts.
- Extending health spans by 40 years is expected to drive demographic changes, including delayed retirement, societal adaptation to longer lifespans with fewer children, and extended reproductive windows for women.
- Societal institutions such as schools, jobs, and retirement age are projected to change slowly, despite individual expectations of living with the energy of youth combined with the wisdom of age.